<?xml version='1.0' encoding='utf-8'?>
<document id="31240576"><sentence text="Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection."><entity charOffset="61-71" id="DDI-PubMed.31240576.s1.e0" text="Ledipasvir" /><entity charOffset="72-82" id="DDI-PubMed.31240576.s1.e1" text="Sofosbuvir" /><pair ddi="false" e1="DDI-PubMed.31240576.s1.e0" e2="DDI-PubMed.31240576.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31240576.s1.e0" e2="DDI-PubMed.31240576.s1.e1" /></sentence><sentence text="Drug-drug interactions need to be considered to optimize the pharmacotherapeutic outcome of direct-acting antivirals" /><sentence text=" The aim of this study was to report on possible drug-drug interactions between ledipasvir/sofosbuvir and other medications received by children and adolescents with hepatitis C virus, in addition to suggested management for these drug-drug interactions"><entity charOffset="80-90" id="DDI-PubMed.31240576.s3.e0" text="ledipasvir" /><entity charOffset="91-101" id="DDI-PubMed.31240576.s3.e1" text="sofosbuvir" /><pair ddi="false" e1="DDI-PubMed.31240576.s3.e0" e2="DDI-PubMed.31240576.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31240576.s3.e0" e2="DDI-PubMed.31240576.s3.e1" /></sentence><sentence text="" /><sentence text="Hepatitis C virus-infected children and adolescents, 12-17 years of age and/or weighing ≥ 35 kg, who presented to the Pediatric Hepatology Unit at Cairo University Pediatric Hospitals for ledipasvir/sofosbuvir treatment were included"><entity charOffset="188-198" id="DDI-PubMed.31240576.s5.e0" text="ledipasvir" /><entity charOffset="199-209" id="DDI-PubMed.31240576.s5.e1" text="sofosbuvir" /><pair ddi="false" e1="DDI-PubMed.31240576.s5.e0" e2="DDI-PubMed.31240576.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31240576.s5.e0" e2="DDI-PubMed.31240576.s5.e1" /></sentence><sentence text=" Medication history was taken including long-term medications for chronic conditions and on-demand medications for inter-current illnesses" /><sentence text=" Medications were reviewed by the Kasr Alainy Drug Information Center to identify possible drug-drug interactions with prescribed ledipasvir/sofosbuvir and their management"><entity charOffset="130-140" id="DDI-PubMed.31240576.s7.e0" text="ledipasvir" /><entity charOffset="141-151" id="DDI-PubMed.31240576.s7.e1" text="sofosbuvir" /><pair ddi="false" e1="DDI-PubMed.31240576.s7.e0" e2="DDI-PubMed.31240576.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31240576.s7.e0" e2="DDI-PubMed.31240576.s7.e1" /></sentence><sentence text=" HEP Drug Interactions provided by the University of Liverpool, Lexicomp®, and Medscape were the utilized references"><entity charOffset="53-62" id="DDI-PubMed.31240576.s8.e0" text="Liverpool" /></sentence><sentence text=" Each drug-drug interaction was assigned a risk rating of A, B, C, D, or X" /><sentence text="" /><sentence text="Sixty hepatitis C virus-infected children and adolescents assigned to receive ledipasvir/sofosbuvir were enrolled"><entity charOffset="78-88" id="DDI-PubMed.31240576.s11.e0" text="ledipasvir" /><entity charOffset="89-99" id="DDI-PubMed.31240576.s11.e1" text="sofosbuvir" /><pair ddi="false" e1="DDI-PubMed.31240576.s11.e0" e2="DDI-PubMed.31240576.s11.e0" /><pair ddi="false" e1="DDI-PubMed.31240576.s11.e0" e2="DDI-PubMed.31240576.s11.e1" /></sentence><sentence text=" Thirty percent of patients had associated chronic co-morbid conditions" /><sentence text=" The overall number of medications received was 48; 39 were prescribed as long-term medications with a median of 3 (interquartile range 4" /><sentence text="24) medications per patient" /><sentence text=" Proton pump inhibitors, antacids, histamine H2 receptor antagonists, sodium bicarbonate, and colchicine were reported to be associated with a drug-drug interaction risk D necessitating therapy modification, which occurred prior to administration"><entity charOffset="35-44" id="DDI-PubMed.31240576.s15.e0" text="histamine" /><entity charOffset="70-88" id="DDI-PubMed.31240576.s15.e1" text="sodium bicarbonate" /><entity charOffset="94-104" id="DDI-PubMed.31240576.s15.e2" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.31240576.s15.e0" e2="DDI-PubMed.31240576.s15.e0" /><pair ddi="false" e1="DDI-PubMed.31240576.s15.e0" e2="DDI-PubMed.31240576.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31240576.s15.e0" e2="DDI-PubMed.31240576.s15.e2" /><pair ddi="false" e1="DDI-PubMed.31240576.s15.e1" e2="DDI-PubMed.31240576.s15.e1" /><pair ddi="false" e1="DDI-PubMed.31240576.s15.e1" e2="DDI-PubMed.31240576.s15.e2" /></sentence><sentence text="" /><sentence text="Early identification and prompt response to drug-drug interactions with the aid of pharmacists optimize the pharmacotherapeutic outcome and eliminate possible morbidities when using direct-acting antivirals in children and adolescents with hepatitis C virus" /><sentence text="" /></document>